To Evaluate the Optimum Dose of Platelet Rich Plasma in Knee Osteoarthritis and Compare Efficacy With Hyaluronic Acid

Launched by DR. HIMANSHU BANSAL FOUNDATION · Dec 12, 2019

Keywords

ClinConnect Summary

Osteoarthritis (OA) causes substantial physical disability that limits a person ability to indulge in daily activities. OA related disability has been affecting millions of older adults throughout the world, and the number has almost doubled in 2019.

Though the process of OA could not be reversed, efficient management strategies could help in minimizing primary pain with physical exercises, surgical procedures, and medications.

Prolonged use of nonsteroidal anti-inflammatory drugs (NSAIDs) has been dramatically associated with mild to severe side effects, limiting its continuous use. Chon...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Outpatients who fulfilled the clinical and radiological criteria set by the American College of Rheumatology for the diagnosis of symptomatic primary knee OA, with pain Visual Analogue Scale (VAS) score of \>3 in the previous month. In cases where both the knees were symptomatic, the knee which was comparatively more painful was considered.
• Exclusion Criteria:
• • 1. Evidence of secondary knee OA because of injury, inflammatory or metabolic rheumatic disease, or osteonecrosis;
• • 2. Prior intra-articular injection of hyaluronic acid (HA), including lavage and corticosteroids within the previous three months;
• • 3. Severe knee OA, with JSW \<1 mm, or surgery required on the evaluated knee in the year
• • 4. Patients with clinically significant systemic disease.